Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMR6N7H)

• Drug Name: Acetohexamide Drug Info
• Synonyms: Acetohexamid; Acetohexamida; Acetohexamidum; Dimelin; Dimelor; Dymelor; Gamadiabet; Hypoglicil; Metaglucina; Minoral; Ordimel; Tsiklamid; Acetohexamide Lilly Brand; Acetohexamide Salvat Brand; Lilly Brand of Acetohexamide; Ord imel; Salvat Brand of Acetohexamide; U 14812; A-178; Acetohexamida [INN-Spanish]; Acetohexamidum [INN-Latin]; Dimelin (antidiabetic); Dymelor (TN); U-14812; Acetohexamide (JP15/USP/INN); Acetohexamide [USAN:INN:BAN:JAN]; N-(p-Acetylbenzenesulfonyl)-N'-cyclohexylurea; N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea; 1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea; 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea; 1-(p-Acetylbenzenesulfonyl)-3-cyclohexylurea; 3-cyclohexyl-1-(p-acetylphenylsulfonyl)urea; 4-Acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)-carbonyl]benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)carbonyl]benzenesulfonamide; 4-acetyl-N-((cyclohexylamino)carbonyl)benzenesulf onamide
• Therapeutic Class: Hypoglycemic Agents
• Cross-matching ID:
  PubChem CID: 1989
  ChEBI ID: CHEMBL28052
  CAS Number: CAS 968-81-0
  TTD Drug ID: D07WFK
  VARIDT Drug ID: DR01113
  INTEDE Drug ID: DR0039

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Ribosome	1.82	3.50e-2	113/158 (71.52%)	MRPS2;RPS5;MRPS16;...
Non-alcoholic fatty liver disease	-1.71	3.96e-2	126/155 (81.29%)	BCL2L11;PPARA;NDUFB4;...
Glyoxylate and dicarboxylate metabolism	-1.73	2.92e-2	23/30 (76.67%)	MDH2;AMT;HYI;...
Regulation of lipolysis in adipocytes	-1.74	2.89e-2	52/55 (94.55%)	TSHR;PIK3R3;PNPLA2;...
Vibrio cholerae infection	-1.75	2.52e-2	44/50 (88%)	SEC61A2;KDELR3;PRKACA;...
Systemic lupus erythematosus	-1.76	2.68e-2	45/135 (33.33%)	C8A;FCGR2A;CD80;...
Citrate cycle (TCA cycle)	-1.80	2.19e-2	30/30 (100%)	PDHA1;PCK2;MDH1;...
Intestinal immune network for IgA production	-1.81	2.50e-2	38/48 (79.17%)	CD80;HLA-DRA;HLA-DRB1;...
Oxidative phosphorylation	-1.82	2.37e-2	93/133 (69.92%)	NDUFB4;SDHB;LHPP;...
Viral myocarditis	-1.86	1.31e-2	53/60 (88.33%)	CD80;FYN;HLA-DRA;...
Protein export	-1.89	8.22e-3	17/23 (73.91%)	SRPRA;SPCS1;SEC11A;...
Valine, leucine and isoleucine degradation	-1.91	1.10e-2	42/48 (87.5%)	ACAD8;ACADS;HMGCL;...
Rheumatoid arthritis	-1.99	0.00e+0	78/93 (83.87%)	TNFSF13;TLR2;ATP6V0B;...
Mineral absorption	-2.15	0.00e+0	48/60 (80%)	MT2A;CYBRD1;HMOX1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	6.66uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.08uM - 20uM	3H, 24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.08uM - 20uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	24H	Show ▼